STXS

Over the past six months, Stereotaxis, Inc. (STXS) stock has experienced a significant decline, with the share price at $1.32 as of September 16, 2026, representing a 52.17% decrease from the previous year. Key events impacting the stock include FDA approvals for the GenesisX endovascular surgical robotics system in November 2025, its proprietary robotically-navigated magnetic ablation catheter in January 2026, and the Synchrony system in April 2026. The company also received European CE mark approval for its proprietary robotically-navigated magnetic ablation catheter in January 2025. Q1 2026 earnings reported a revenue decline due to the transition from legacy products, but strong demand for new catheters and digital systems, along with the Robocath acquisition, supported a double-digit revenue growth guidance for 2026, while Q2 2026 earnings reported a loss per share of $0.048, meeting analyst expectations, but revenue of $7.67 million lagged behind estimates. Several analysts, including Citizens JMP and TD Cowen, lowered their price targets for STXS to $3.00 in August 2026, while maintaining 'Buy' or 'Market Outperform' ratings, with the average analyst price target predicting a 132.56% increase. In July 2026, Stereotaxis filed shelf registrations covering up to approximately $205.3 million of common equity, which could lead to dilution and act as a supply overhang.